Compound: cilostazol
SMILES: O=C1Nc2c(cc(OCCCCc3nnnn3C4CCCCC4)cc2)CC1
InChIKey: RRGUKTPIGVIEKM-UHFFFAOYSA-N
Synonyms: cilostazol, 73963-72-1, Pletal, Cilostazole, Pletaal, OPC-13013, Cilostazolum, OPC-21, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, NSC-758936, DTXSID9045132, CHEBI:31401, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril, N7Z035406B, DTXCID7025132, 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-, 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy)-3,4-dihydro-1H-quinolin-2-one, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one, RefChem:58562, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butyloxy)-3,4-dihydroquinolin-2(1H)-one, Cilostazolum [INN-Latin], 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one, C20H27N5O2, MFCD00866780, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one, MLS000028470, 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one, NCGC00015207-07, SMR000058428, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 21, CAS-73963-72-1, Pletal (TN), SR-01000003107, BRN 3632107, UNII-N7Z035406B, Cilostazol [USAN:USP:INN:BAN:JAN], Cilostazol (Standard), Tocris-1692, CILOSTAZOL [MI], Opera_ID_488, CILOSTAZOL [INN], CILOSTAZOL [JAN], Spectrum2_001118, Spectrum3_001170, Spectrum4_000772, Spectrum5_001762, CILOSTAZOL [USAN], Lopac-C-0737, CILOSTAZOL [VANDF], CHEMBL799, C 0737, CILOSTAZOL [MART.], CILOSTAZOL [USP-RS], CILOSTAZOL [WHO-DD], Lopac0_000218, REGID_for_CID_2754, SCHEMBL16128, BSPBio_002759, KBioGR_001184, MLS000758281, MLS000759507, MLS001076067, MLS002153891, SPECTRUM1505230, SPBio_001256, Cilostazol (JP18/USP/INN), GTPL7148, orb1310589, orb3141224, CILOSTAZOL [ORANGE BOOK], SCHEMBL27771101, SCHEMBL29389547, HSDB 8312, KBio3_002259, CILOSTAZOL [USP MONOGRAPH], HMS1922N15, HMS2093M14, HMS2096F16, HMS2234C06, HMS3260L17, HMS3268O09, HMS3412B18, HMS3654J13, HMS3676B18, HMS3713F16, HMS5079N07, Pharmakon1600-01505230, Tox21_110098, Tox21_500218, BDBM50225508, CCG-39646, EBC-11191, HY-17464R, MSK160188, NSC758936, s1294, AKOS015855512, Cilostazol, >=98% (HPLC), powder, OPC 13013; OPC 21; Pletaal, Tox21_110098_1, AC-4334, CS-1759, DB01166, FC03161, KS-5154, LP00218, NSC 758936, SDCCGSBI-0050206.P003, 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-, NCGC00015207-01, NCGC00015207-02, NCGC00015207-03, NCGC00015207-04, NCGC00015207-05, NCGC00015207-06, NCGC00015207-08, NCGC00015207-09, NCGC00015207-10, NCGC00015207-11, NCGC00015207-12, NCGC00015207-25, NCGC00022153-02, NCGC00022153-04, NCGC00022153-05, NCGC00022153-06, NCGC00022153-07, NCGC00260903-01, HY-17464, SBI-0050206.P002, C2587, EU-0100218, NS00009762, SW199053-2, T0462, D01896, F20538, AB00382988-14, AB00382988_15, AB00382988_16, F862750, Q258591, SR-01000003107-2, SR-01000003107-4, SR-01000003107-7, BRD-K67017579-001-04-2, BRD-K67017579-001-05-9, BRD-K67017579-001-07-5, BRD-K67017579-001-13-3, BRD-K67017579-001-17-4, BRD-K67017579-001-26-5, BRD-K67017579-001-27-3, BRD-K67017579-001-28-1, SR-01000003107-10, Z1501485368, Cilostazol, United States Pharmacopeia (USP) Reference Standard, 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril, Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material, 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE, 6-[4-(1-Cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone
Theoretical properties:
molecular_formula: C20H27N5O2
molecular_weight: 369.5 g/mol
exact_mass: 369.21647512 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 7
heavy_atom_count: 27
topological_polar_surface_area: 81.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Colorless needle-like crystals from methanol
color: Colorless needle-like crystals from methanol
solubility: Practically insoluble in water
Descriptions:
pubchem: Cilostazol is a lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group. It has a role as a bronchodilator agent, a vasodilator agent, a fibrin modulating drug, an anticoagulant, a platelet aggregation inhibitor, an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor and a neuroprotective agent. It is a lactam and a member of tetrazoles.
chebi: A lactam that is 3,4-dihydroquinolin-2(1<em>H</em>)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1<em>H</em>-tetrazol-5-yl)butoxy group.
chembl: CILOSTAZOL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Cilostazol, sold under the brand name Pletal among others, is a medication used to help the symptoms of intermittent claudication in peripheral vascular disease. It may also be used to prevent stroke. It is taken by mouth.
Common side effects include headache, diarrhea, dizziness, and cough. Serious side effects may include decreased survival in those with heart failure, low platelets, and low white blood cells. Cilostazol is a phosphodiesterase 3 inhibitor which works by inhibiting platelet aggregation and dilating arteries.
Cilostazol was approved for medical use in the United States in 1999. It is available as a generic medication. In 2019, it was the 347th most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.